Prognosis of Non-Small Cell Lung Cancer

Overall Survival by Stage

The National Comprehensive Cancer Network recommends that the prognosis of NSCLC is heavily stage-dependent, with 5-year survival rates ranging from 52% for localized disease to only 3.7% for distant metastatic disease 1
The 5-year survival rate for localized disease is 52%, representing only 15% of cases at diagnosis, as stated by the National Comprehensive Cancer Network 1, 2, 3
The 5-year survival rate for regional disease is 25%, accounting for 22% of cases, according to the National Comprehensive Cancer Network 1, 2
The 5-year survival rate for distant metastatic disease is 3.7%, comprising 56% of cases at diagnosis, as reported by the National Comprehensive Cancer Network 1, 2, 3
The overall 5-year survival across all stages is approximately 15-16%, as stated by the National Comprehensive Cancer Network and Annals of Oncology 1, 4, 5

The American College of Chest Physicians states that stage IA has a 73% 5-year survival rate 4
The American College of Chest Physicians reports that stage IB has a 58% 5-year survival rate 4
The American College of Chest Physicians recommends that stage I overall has a 60-80% 5-year survival rate with radical surgical resection 6
The American College of Chest Physicians states that stage II has a 30-50% 5-year survival rate 6
The American College of Chest Physicians recommends that unresectable stage III has approximately 20% 5-year survival with concurrent chemoradiotherapy 7

The American College of Chest Physicians states that mediastinal lymph node involvement, such as N2/N3 disease, significantly worsens prognosis 8, 9
The American College of Chest Physicians recommends that the number and location of metastases, such as oligometastatic disease, have better prognosis with surgical resection 8

The American College of Chest Physicians states that patients with isolated metastases to brain or adrenal glands who undergo complete surgical resection can achieve 5-year survival of 25-32% 8
The American College of Chest Physicians reports that synchronous isolated adrenal metastasis has a 26% 5-year survival rate with resection 8
The American College of Chest Physicians states that metachronous isolated adrenal metastasis has a 25% 5-year survival rate with resection 8
The American College of Chest Physicians recommends that highly selected T4 N0-1 M0 patients achieving complete resection can have prolonged survival, though operative mortality is relatively high (7-14%) 9
The American College of Chest Physicians states that carinal involvement has a 28% 5-year survival rate (average), up to 44% in high-volume centers 9
The American College of Chest Physicians reports that SVC involvement has a 20-25% 5-year survival rate, improving to 28-31% in recent series 9
The American College of Chest Physicians states that aortic involvement has a 25-50% 5-year survival rate with complete resection 9

The National Comprehensive Cancer Network recommends that EGFR mutations and ALK rearrangements are predictive biomarkers that indicate treatment benefit with targeted therapies but do not independently predict survival 1, 2, 3
The National Comprehensive Cancer Network states that EGFR exon 19 deletion or L858R mutation predicts response to EGFR-TKI therapy (erlotinib, gefitinib) 1, 2
The National Comprehensive Cancer Network recommends that ALK gene rearrangement predicts response to crizotinib 1, 2

In patients with stage III non‑small cell lung cancer (NSCLC) who undergo bilobectomy, the overall 5‑year survival is approximately 30 %–40 %, which is markedly lower than the survival after standard lobectomy and approaches the poor outcomes seen with pneumonectomy. 10
Complete surgical resection of stage IIIA NSCLC yields a 5‑year survival range of 23 %–40 %, with the exact figure varying according to nodal involvement. 10

When mediastinal (N2) nodal disease is present, the 5‑year survival after bilobectomy falls to roughly 30 %–40 %; in contrast, patients with N0 disease achieve higher survival (approximately 69 %). 10

Cisplatin‑based adjuvant chemotherapy is recommended for resected stage IIIA NSCLC and has been shown to improve survival outcomes in this population. 10

For patients aged 60–69 years, the peri‑operative (30‑day) mortality after standard lobectomy is about 5 %–6 %; bilobectomy in the same age bracket carries a substantially higher risk. 11
The same age‑related mortality data are corroborated by an additional analysis from the same journal, reinforcing the elevated risk associated with more extensive resections. 12